Finance & Capital Markets

51. Biotech M&A Trends With Allan Shaw 3/21/2022

    On this episode of the Business of Biotech, Allan Shaw waxes on his expectations for mergers, acquisitions, and collaborative partnership opportunities for new and emerging biotechs in 2022 and beyond. We tackle questions biotech leaders should be asking about intentionality, what's attractive to potential suitors, and why startups that aren't prepared to take a candidate to the finish line have already conceded a major factor in partnership or buyout negotiations. Don't miss Shaw's advice for startup success in a suddenly tumultuous market.

52. Biotech M&A Anomalies With Allan Shaw 8/22/2022

    While many clinical-stage biopharmas are contracting or holding the line through the current market slump, Portage Biotech leaders Ian Walters, Allan Shaw, and company are making moves. The company recently acquired Tarus Therapeutics and iOx Therapeutics Ltd., extending its pipeline and positioning itself to meet some aggressive investor expectations. On this episode of the Business of Biotech, Shaw dissects the deals, digging into the M&A strategy at Portage and offering advice from the batter's box to leaders of early-stage biotechs.

53. The Innovator's Dilemma with Lumen Bioscience's Brian Finrow, J.D. 3/4/2024

    In biotech, when "one of these things doesn't look like the other one," it can be a blessing or a curse. On one hand, scientific novelty is praised and rewarded. On the other, unfamiliarity breeds skepticism from the investment community. Brian Finrow, J.D. embraces that reality and the challenges that come with it.

54. Picking Biotech Jockeys With SR One's Simeon George, M.D. 9/15/2024

    SR One Capital Management CEO Simeon George, M.D. has a seemingly innate ability to pick winning biotech builders. On the Business of Biotech, Dr. George shares insight into the decision-making processes that have contributed to his success at picking winners as an investment banker and biotech venture capitalist. Listen now!

55. Biotech Cash Management With Allan Shaw 8/2/2023

    It’s been said that clinical trials are where emerging biotechs go to die. If the science doesn't kill quickly, poor cash management will slowly. On this week's episode of the Business of Biotech, our favored biotech finance management maven, Allan Shaw, offers pointed advice on stretching cash runways for the long run.

56. Financing Biopharma Innovation With Allan Shaw 12/19/2022

    Friend and frequent guest Allan Shaw rejoins the Business of Biotech to reflect on his recent presentation on innovative biotech financing at the BioFuture event in NYC. We also dig into Bruce Booth's "Atlas Venture Year In Review," revisiting and unpacking some quoteworthy material and metrics from both sources. Allan offers up plenty of prognostication and professional insight in a preview of what's to come in 2023, complete with his signature "Allanisms" and colorful analogies. A can't-miss episode as we round the turn to a new year!

57. The Allogeneic Future with Poseida's Kristin Yarema, Ph.D. 8/4/2024

    Kristin Yarema, Ph.D. thinks the progress of CAR T therapeutics is allogeneic. In fact, she says CAR T-cell therapies have to become a one-to-many proposition, if their early autologous success can possibly live up to the promise of offering widespread accessibility to life-saving treatments. On this episode of the Business of Biotech, we'll learn about how the newly-appointed CEO of Poseida Therapeutics earned the company's reins, how Poseida is positioning itself to crack the allogeneic CAR T code, and how strategic collaborations with the likes of Astellas and Roche are fueling the effort. 

58. Funding Alzheimer's Tx Dev with ADDF's Karen Harris 3/31/2024

    We've really been looking forward to dropping this episode with Karen Harris, Chief Financial Officer and Head of Mission-Related Investing at the Alzheimer's Drug Discovery Foundation. While the markets have warmed a bit since we recorded this episode, Karen's thoughtful perspective on the sometimes tumultuous Alzheimer's therapeutics space is valuable to any drug developer working in the cognitive medicines arena.

59. Building Flagship Pioneering With Avak Kahvejian, Ph.D. 4/26/2023

    Flagship Pioneering is fertile ground for a bevy of blossoming biotechs, and one of its most prolific sowers is General Partner Avak Kahvejian, Ph.D. Dr. Kahvejian counts Seres Therapeutics, Rubius Therapeutics, Codiak BioSciences, Cygnal Therapeutics, Ring Therapeutics, Cellarity, Laronde, and Generate Biomedicines among the companies he's played a leading hand in launching. On this episode of the Business of Biotech, Kahvejian takes us under the hood of one of the most burgeoning businesses in biotech, sharing details on the people, processes, and technologies fueling its rapid growth.

60. BoB@JPM: Tom Chalberg, Ph.D., Genascence 2/23/2025

    This episode of the Business of Biotech finds Matt Pillar and Ben Comer exploring the evolution of gene therapy with Dr. Tom Chalberg, Founder, Chairman, & CEO at Genascence. Listen in as they discuss ATMPS' transition from treating rare diseases to addressing common conditions like osteoarthritis, share insights on the delivery mechanism and regulatory challenges in the space, and get into the nuts and bolts of the Genascence partnership strategy.